Skip to main content
CGC
NASDAQ Life Sciences

Canopy Growth Registers 18.7M Shares for Resale by Lenders from Recent Loan Warrants

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$1.11
Mkt Cap
$401.14M
52W Low
$0.77
52W High
$2.9
52W Position info
44% above low
Off High info
62% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

CGC sits 44% above its 52-week low of $0.77 on light trading volume (0.4× avg).

Summary

Canopy Growth Corp filed an S-3 registration statement for the resale of 18.7 million common shares by selling securityholders, which are issuable upon the exercise of Loan Warrants issued as part of a recent $150 million senior secured loan.


Key Events · Financing and Capital Events · CGC

  • Resale Registration Filed

    Canopy Growth Corp has registered 18,705,578 common shares for resale by selling securityholders.

  • Shares from Loan Warrants

    These shares are issuable upon the exercise of Loan Warrants, which were issued to lenders on January 8, 2026, as part of a $150 million senior secured loan.

  • Warrant Exercise Price

    Each Loan Warrant has an exercise price of US$1.30 per share and will expire on January 8, 2031.

  • Potential Dilution

    The 18.7 million shares represent approximately 4.95% of the company's currently outstanding common shares, creating a potential overhang.


Analysis · CGC · Life Sciences

This S-3 filing formalizes the ability for lenders, who received Loan Warrants as part of the $150 million senior secured loan on January 8, 2026, to resell the underlying common shares. While the company will not directly receive proceeds from these resales, the registration creates a significant overhang on the stock. The 18.7 million shares represent a notable potential dilution of approximately 4.95% of current outstanding shares. The warrants' exercise price of $1.30 is currently above the stock's closing price of $1.11, meaning they are out-of-the-money. This reduces immediate selling pressure but indicates a substantial block of shares could enter the market if the stock price recovers. This event follows a series of recent dilutive financing activities and resale registrations, highlighting the company's ongoing need for capital and the associated shareholder dilution.

At the time of this filing, CGC was trading at $1.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $401.1M. The 52-week trading range was $0.77 to $2.90. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CGC - Latest Insights

CGC
Jul 17, 2026, 4:25 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.9549
Real-time Price: $0.8954 info
Change: -$0.0595 (-6%) info
Market Cap: $398.365M info
CGC
Jun 15, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $0.965
Real-time Price: $0.8954 info
Change: -$0.0696 (-7%) info
Market Cap: $398.365M info
CGC
Jun 15, 2026, 6:46 AM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $1.01
Real-time Price: $0.8954 info
Change: -$0.1146 (-11%) info
Market Cap: $398.365M info
CGC
May 15, 2026, 5:06 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.03
Real-time Price: $0.8954 info
Change: -$0.1346 (-13%) info
Market Cap: $398.365M info
CGC
Mar 16, 2026, 7:59 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.03
Real-time Price: $0.8954 info
Change: -$0.1346 (-13%) info
Market Cap: $398.365M info